Filtered By:
Specialty: Biotechnology
Cancer: Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 116 results found since Jan 2013.

Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA-PLGA/CSO conjugate micelles.
Abstract Biodegradable and biocompatible poly(d,l-lactic-co-glycolic acid) (PLGA)was conjugated to the 5'-thiol end of signal transducer and activator of transcription 3 (STAT3) small interfering RNA (STAT3-siRNA) via a disulfide bond. In aqueous environments, these siRNA-PLGA conjugates can spontaneously form core/shell type spherical micelles with a particle size of about 200nm. A biodegradable, low molecular weight cationic polymer, chitosan oligosaccharide (CSO), was added to the siRNA-PLGA micelles at different nitrogen to phosphate (N/P) ratios to form stable, spherical siRNA-PLGA/CSO micelles with sizes of ...
Source: Colloids and Surfaces - January 28, 2015 Category: Biotechnology Authors: Zhao Y, Zheng C, Zhang L, Chen Y, Ye Y, Zhao M Tags: Colloids Surf B Biointerfaces Source Type: research

Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy.
In conclusion, the application of siRNA-CPPs/TML under an AC magnetic field represents a new strategy for the selective and efficient delivery of siRNA. PMID: 27429294 [PubMed - as supplied by publisher]
Source: Colloids and Surfaces - July 1, 2016 Category: Biotechnology Authors: Yang Y, Xie X, Xu X, Xia X, Wang H, Li L, Dong W, Ma P, Yang Y, Liu Y, Mei X Tags: Colloids Surf B Biointerfaces Source Type: research

Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review.
Abstract Co-delivery of chemotherapy drugs and siRNA for cancer therapy has achieved remarkable results according to synergistic/combined antitumor effects, and is recognized as a promising therapeutic modality. However, little attention has been paid to the extremely complex mechanisms of chemotherapy drug-siRNA pairs during co-delivery process. Proper selection of chemotherapy drug-siRNA pairs is beneficial for achieving desirable cancer therapeutic effects. Exploring the inherent principles during chemotherapy drug-siRNA pair selection for co-delivery would greatly enhanced therapeutic efficiency. To achieve id...
Source: Colloids and Surfaces - June 8, 2017 Category: Biotechnology Authors: Wang M, Wang J, Li B, Meng L, Tian Z Tags: Colloids Surf B Biointerfaces Source Type: research

Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery.
Abstract Small interfering RNAs (siRNA) are short nucleic acid fragments of about 20-27 nucleotides, which can inhibit the expression of specific genes. siRNA based RNAi technology has emerged as a promising method for the treatment of a variety of diseases. However, a major limitation in the therapeutic use of siRNA is its rapid degradation in plasma and cellular cytoplasm, resulting in short half-life. In addition, as siRNA molecules cannot penetrate into the cell efficiently, it is required to use a carrier system for its delivery. In this work, chemically and morphologically different calcium phosphate (CaP) n...
Source: Colloids and Surfaces - June 27, 2017 Category: Biotechnology Authors: Bakan F, Kara G, Cokol Cakmak M, Cokol M, Denkbas EB Tags: Colloids Surf B Biointerfaces Source Type: research

Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy.
In conclusion, our novel PEGylated liposomes have high potential for systemic delivery of siRNA and can improve in vivo stability of free siRNA and also siRNA lipoplexes. PMID: 29475393 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - February 26, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: Effect of degree of PEG grafting on biological and cellular activity.
Authors: Safari F, Tamaddon AM, Zarghami N, Abolmali S, Akbarzadeh A Abstract Gene silencing by siRNA (short interfering RNA)-targeted human telomerase reverse transcriptase (hTERT) is considered a successful strategy for cancer gene therapy. Polyelectrolyte complexes (PEC) of siRNA and cationic polymers such as polyethyleneimine (PEI) have been widely used for cellular transfection; however, they demonstrate some disadvantages such as cytotoxicity and extracellular matrix restrictions. PEG grafting technology was used in an attempt to improve the biocompatibility of PECs. Considering that this technology may compr...
Source: Artificial Cells, Nanomedicine and Biotechnology - December 12, 2015 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells.
Abstract The aim of this study is to improve hydrocolloid stability and siRNA transfection ability of a reduced graphene oxide (rGO) based nano-carrier using a phospholipid-based amphiphilic polymer (PL-PEG) and cell penetrating peptide (CPPs). The dual functionalized nano-carrier is comprehensively characterized for its chemical structure, size, surface charge and morphology as well as thermal stability. The nano-carrier cytocompatibility, siRNA condensation ability both in the presence and absence of enzyme, endosomal buffering capacity, cellular uptake and intracellular localization are also assessed. The siRNA...
Source: Colloids and Surfaces - August 11, 2016 Category: Biotechnology Authors: Imani R, Shao W, Taherkhani S, Emami SH, Prakash S, Faghihi S Tags: Colloids Surf B Biointerfaces Source Type: research

Preparation and characterization of silk fibroin/oligochitosan nanoparticles for siRNA delivery.
In this study, oligochitosan (OC) combined with silk fibroin (SF) was formulated and proposed as a novel carrier for siRNA. The obtained SF/OC/siRNA nanoparticles (NPs) were characterized according to their physicochemical properties, such as their size, zeta potential, loading efficiency, stability, cytotoxicity, cellular uptake and transfection efficiency, and their properties were compared with those of OC polyplexes. The mean diameter of SF/OC/siRNA NPs was not significantly different compared to polyplexes, and the particle size ranged between 250 and 450nm. Increased amounts of SF in NPs enhanced their loading effici...
Source: Colloids and Surfaces - November 2, 2015 Category: Biotechnology Authors: Shahbazi B, Taghipour M, Rahmani H, Sadrjavadi K, Fattahi A Tags: Colloids Surf B Biointerfaces Source Type: research

Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.
Abstract RNA interference (RNAi) is an evolutionary conserved highly specific gene-silencing mechanism initiated by small interfering RNA (siRNA) molecules. Fast-paced preclinical and clinical studies helped the siRNA technology become an efficient tool for undruggable targets in different diseases including genetic diseases, viral diseases and cancer. Despite great feature of siRNAs that can down-regulate any protein in the cells, the full potential and the success of the preclinical studies could not be translated into largely successful clinical outcomes. It has become clear that the possibility of overcoming t...
Source: Current Pharmaceutical Biotechnology - March 31, 2016 Category: Biotechnology Authors: Sarisozen C, Salzano G, Torchilin VP Tags: Curr Pharm Biotechnol Source Type: research

Near-infrared light-activatable siRNA delivery by microcapsules for combined tumour therapy.
Authors: Rui Y, Pang B, Zhang J, Liu Y, Hu H, Liu Z, Ama Baidoo S, Liu C, Zhao Y, Li S Abstract A polyelectrolyte microcapsule-based layer-by-layer (LbL) technique has been widely used as a multifunctional vehicle for combined tumor therapy. Meanwhile, with the rapid development of combined tumour therapy, the challenge for designing multifunctional drug delivery system has attracted much more attention. Herein, we developed a new type of microcapsule (MC) system called MPA@siRNA@DOX@MC, which conjugated with siRNA and DOX as well as ICG-Der-02 (MPA) by electrostatic absorption. MPA as indocyanine green (ICG) fluor...
Source: Artificial Cells, Nanomedicine and Biotechnology - March 14, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Rigid nanoparticle-based delivery of anti-cancer siRNA: Challenges and opportunities.
Abstract Gene therapy is a promising strategy to treat various genetic and acquired diseases. Small interfering RNA (siRNA) is a revolutionary tool for gene therapy and the analysis of gene function. However, the development of a safe, efficient, and targetable non-viral siRNA delivery system remains a major challenge in gene therapy. An ideal delivery system should be able to encapsulate and protect the siRNA cargo from serum proteins, exhibit target tissue and cell specificity, penetrate the cell membrane, and release its cargo in the desired intracellular compartment. Nanomedicine has the potential to deal with...
Source: Biotechnology Advances - September 4, 2013 Category: Biotechnology Authors: Wang Z, Liu G, Zheng H, Chen X Tags: Biotechnol Adv Source Type: research

Advances in siRNA delivery in cancer therapy.
Authors: Singh A, Trivedi P, Jain NK Abstract RNA interference (RNAi)-based therapeutic approaches are under vibrant scrutinisation to seek cancer cure. siRNA suppress expression of the carcinogenic genes by targeting the mRNA expression. However, in vivo systemic siRNA therapy is hampered by the barriers such as poor cellular uptake, instability under physiological conditions, off-target effects and possible immunogenicity. To overcome these challenges, systemic siRNA therapy warrants the development of clinically suitable, safe, and effective drug delivery systems. Herein, we review the barriers, potential siRNA ...
Source: Artificial Cells, Nanomedicine and Biotechnology - April 22, 2017 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy.
Authors: Hemati M, Haghiralsadat F, Yazdian F, Jafari F, Moradi A, Malekpour-Dehkordi Z Abstract The aim of this study was to optimize the cationic PEGylated niosome-containing anti-cancer drugs and siRNA to enhance the therapeutic response. Therefore, various surfactant-based (tween-60) vesicles of doxorubicin (DOX; a chemotherapeutic drug) and quercetin (QC; a chemosensitizer) were prepared. To load siRNA on niosomes, 1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) was used as a cationic lipid. The optimum formulation containing tween-60:cholesterol:DPPC:DOTAP:DSPE-PEG2000 at 49.5:5.5:15:25:5 demonstrated that ...
Source: Artificial Cells, Nanomedicine and Biotechnology - July 24, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells.
Abstract Co-delivery of therapeutic agents and small interfering RNA (siRNA) can be achieved by a suitable nanovehicle. In this work, the solubility and bioavailability of curcumin (Cur) were enhanced by entrapment in a polyamidoamine (PAMAM) dendrimer, and a polyplex was formed by grafting Bcl-2 siRNA onto the surface amine groups to produce PAMAM-Cur/Bcl-2 siRNA nanoparticles (NPs). The synthesized polyplex NPs had a particle size of ∼180 nm, and high Cur loading content of ∼82 wt%. Moreover, the PAMAM-Cur/Bcl-2 siRNA NPs showed more effective cellular uptake, and higher inhibition of tumor cell proliferat...
Source: Colloids and Surfaces - December 26, 2019 Category: Biotechnology Authors: Ghaffari M, Dehghan G, Baradaran B, Zarebkohan A, Mansoori B, Soleymani J, Ezzati Nazhad Dolatabadi J, Hamblin MR Tags: Colloids Surf B Biointerfaces Source Type: research

VEGF siRNA delivery by a cancer-specific cell-penetrating peptide.
In this study, we investigated the efficacy of the cancer-specific CPP carrier BR2 to specifically transport siRNA to cancer-target cells. Our results showed that BR2 formed a complex with anti-vascular endothelial growth factor siRNA (siVEGF) that exhibited the appropriate size and surface charge for in vivo treatment. Additionally, the BR2-VEGF siRNA complex exhibited significant serum stability and high levels of gene-silencing effects in vitro. Moreover, the transfection efficiency of the complex into a cancer cell line was higher than that observed in non-cancer cell lines, resulting in downregulated intracellular VEG...
Source: Journal of Microbiology and Biotechnology - January 11, 2018 Category: Biotechnology Authors: Lee YW, Hwang YE, Lee JY, Sohn JH, Sung BH, Kim SC Tags: J Microbiol Biotechnol Source Type: research